Chimeric Therapeutics (ASX:CHM) has opened the Phase 1B ADVENT-AML clinical trial to enrolment at The University of Texas MD Anderson Cancer Centre.
The ADVENT-AML Phase 1B study is evaluating Chimeric’s off-the-shelf universal donor NK cell therapy CHM 0201 in combination with standard of care therapy for patients with newly diagnosed Acute Myeloid Leukemia (AML).
The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated study at The University of Texas MD Anderson Cancer Center under Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia.
The study is the first trial to evaluate the synergy of NK cell therapy in combination with the current standard of care, Azacitidine and Venetoclax. The study is designed to enrol up to 20 subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant, following an initial dose confirmation cohort assessing the safety of this novel combination treatment in subjects with relapsed or refractory AML.
“We are very excited that the ADVENT AML clinical trial is now open to enrolment as it marks a first and important milestone in the investigation of NK cells in combination with current AML standard of care therapy,” said Jennifer Chow, CEO and Managing Director of Chimeric Therapeutics.
“With the high unmet medical needs in AML and the promising synergy demonstrated with NK cells in combination with Azacitidine and Venetoclax, this trial has potential to significantly enhance outcomes for AML patients.”
Under the terms of the clinical trial agreement with MD Anderson, Chimeric will provide CHM 0201 study drug as well as partial financial support for study. In addition to the modest financial support from Chimeric, the study will be supported by grant funding from multiple funding sources including Gateway for Cancer Research.